About Avidity Biosciences
Avidity Biosciences is a company based in San Diego (United States) founded in 2012 was acquired by Novartis in October 2025. Avidity Biosciences has raised $142.54 million across 7 funding rounds from investors including Lilly, Novartis and ARE. The company has 391 employees as of December 31, 2024. Avidity Biosciences offers products and services including AOC Platform and Pipeline for DM1. Avidity Biosciences operates in a competitive market with competitors including Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
- Headquarter San Diego, United States
- Employees 391 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avidity Biosciences, Inc.
-
Annual Revenue
$10.9 M (USD)13.99as on Dec 31, 2024
-
Net Profit
-$322.3 M (USD)-51.87as on Dec 31, 2024
-
EBITDA
-$376.16 M (USD)-61.1as on Dec 31, 2024
-
Total Equity Funding
$142.54 M (USD)
in 7 rounds
-
Latest Funding Round
$400.21 M (USD), Post-IPO
Mar 04, 2024
-
Investors
Lilly
& 18 more
-
Employee Count
391
as on Dec 31, 2024
-
Acquired by
Novartis
(Oct 27, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Avidity Biosciences
Avidity Biosciences is a publicly listed company on the NASDAQ with ticker symbol RNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Avidity Biosciences
Avidity Biosciences offers a comprehensive portfolio of products and services, including AOC Platform and Pipeline for DM1.
Platform combines antibodies and oligonucleotides for targeted disease treatment.
Develops treatments for myotonic dystrophy type 1 and related conditions.
People of Avidity Biosciences
Unlock access to complete
Unlock access to complete
Leadership Team
56 people
Software Development Team
32 people
Senior Team
19 people
Operations Team
14 people
Associate Team
14 people
Product Management Team
13 people
Principal Team
11 people
Data Analysis and Operations Team
10 people
Unlock access to complete
Funding Insights of Avidity Biosciences
Avidity Biosciences has successfully raised a total of $142.54M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $400.21 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Avidity Biosciences
Avidity Biosciences has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Lilly, Novartis and ARE.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Private equity fund focused on the biotechnology sector
|
Locked | Locked | Locked |
Investor details for Avidity Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avidity Biosciences
Investment portfolio details for Avidity Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Avidity Biosciences
Detailed financials for Avidity Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avidity Biosciences Comparisons
Peer comparison for Avidity Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avidity Biosciences
Avidity Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, GSK, C4 Therapeutics, Erasca and MiRagen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Avidity Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avidity Biosciences
Complete news archive for Avidity Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avidity Biosciences
Avidity Biosciences was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Avidity Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Sarah Boyce is the current CEO of Avidity Biosciences.
Avidity Biosciences is a funded company, having raised a total of $142.54M across 7 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Avidity Biosciences is 391.
Annual revenue of Avidity Biosciences is $10.9M as on Dec 31, 2024.
Avidity Biosciences was founded in 2012 in San Diego, United States, within the biotechnology sector focused on oncology. Antibody-siRNA complexes, known as ARCs, are advanced to combine elements of antibody-drug conjugates and nucleic acid therapeutics. Targeted polymeric nanoparticles encapsulating siRNA payloads are created for delivery to specific tumor types. These nanoparticles are decorated with antibodies, proteins, peptides, or small molecules to enable binding to extracellular receptors and promote cellular uptake.
Avidity Biosciences's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Avidity Biosciences offers AOC Platform and Pipeline for DM1.
Yes, Avidity Biosciences is publicly traded on NASDAQ under the ticker symbol RNA.
Avidity Biosciences has 19 investors. Key investors include Lilly, Novartis, ARE, TPG, and RTW Investments.
The ticker symbol of Avidity Biosciences is RNA on NASDAQ.